The stock of Ovid Therapeutics Inc (OVID) has seen a -15.16% decrease in the past week, with a -23.57% drop in the past month, and a -62.39% decrease in the past quarter. The volatility ratio for the week is 13.40%, and the volatility levels for the past 30 days are at 10.85% for OVID. The simple moving average for the past 20 days is -19.15% for OVID’s stock, with a -60.60% simple moving average for the past 200 days.
Is It Worth Investing in Ovid Therapeutics Inc (NASDAQ: OVID) Right Now?
Additionally, the 36-month beta value for OVID is 0.26. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for OVID is 56.63M and currently, short sellers hold a 1.77% ratio of that float. The average trading volume of OVID on March 14, 2025 was 393.54K shares.
OVID) stock’s latest price update
Ovid Therapeutics Inc (NASDAQ: OVID)’s stock price has dropped by -12.00 in relation to previous closing price of 0.50. Nevertheless, the company has seen a loss of -15.16% in its stock price over the last five trading days. zacks.com reported 2025-03-11 that Ovid Therapeutics (OVID) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.22 per share a year ago.
Analysts’ Opinion of OVID
B. Riley Securities, on the other hand, stated in their research note that they expect to see OVID reach a price target of $9. The rating they have provided for OVID stocks is “Buy” according to the report published on April 30th, 2024.
H.C. Wainwright gave a rating of “Buy” to OVID, setting the target price at $9 in the report published on April 29th of the previous year.
OVID Trading at -34.85% from the 50-Day Moving Average
After a stumble in the market that brought OVID to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.25% of loss for the given period.
Volatility was left at 10.85%, however, over the last 30 days, the volatility rate increased by 13.40%, as shares sank -28.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -54.65% lower at present.
During the last 5 trading sessions, OVID fell by -15.16%, which changed the moving average for the period of 200-days by -85.38% in comparison to the 20-day moving average, which settled at $0.5443. In addition, Ovid Therapeutics Inc saw -52.88% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OVID starting from ALEXANDER MARGARET A., who sale 5,279 shares at the price of $0.56 back on Feb 26 ’25. After this action, ALEXANDER MARGARET A. now owns 73,406 shares of Ovid Therapeutics Inc, valued at $2,956 using the latest closing price.
Rona Jeffrey A, the CBFO of Ovid Therapeutics Inc, sale 3,902 shares at $0.56 during a trade that took place back on Feb 26 ’25, which means that Rona Jeffrey A is holding 67,973 shares at $2,185 based on the most recent closing price.
Stock Fundamentals for OVID
Current profitability levels for the company are sitting at:
- -109.33 for the present operating margin
- 0.5 for the gross margin
The net margin for Ovid Therapeutics Inc stands at -46.7. The total capital return value is set at -0.76. Equity return is now at value -36.60, with -28.55 for asset returns.
Based on Ovid Therapeutics Inc (OVID), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -3.79.
Currently, EBITDA for the company is -61.88 million with net debt to EBITDA at 0.19. When we switch over and look at the enterprise to sales, we see a ratio of 34.85. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.66.
Conclusion
In conclusion, Ovid Therapeutics Inc (OVID) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
